RxDoctor Payments Data

Mark Wernham, PA

Medical · Ithaca, NYNPI 1205849981

Payments from drug & device makers

$3,802in general payments, 2019–2025

Across 188 payments — averaging $20.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$614
  • AbbVie$475
  • Regeneron Healthcare Solutions, Inc.$377
  • Novartis$376
  • Lilly USA, LLC$354
  • Sun Pharmaceutical Industries Inc.$252
  • plus $1K from 14 others

What the payments were for

  • Food & beverage$3,60195%
  • Education$2015%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,802 in reported general payments places this provider in the 85th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$179,072
Medicare patients
1,036
Services billed
3,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa12$249,257
OtezlaApremilast20$91,874
Clobetasol Propionate98$5,574
Sulfacetamide Sodium15$2,248
Ketoconazole130$2,136
Clindamycin Phosphate45$1,971
Tacrolimus19$1,869
Metronidazole35$1,866
Betamethasone Dipropionate22$1,610
Fluocinolone AcetonideFluocinolone/Shower Cap17$1,430
CiclopiroxCiclopirox Olamine34$1,107
Triamcinolone Acetonide97$1,101
Fluorouracil15$833
Fluocinonide17$775
Doxepin Hcl14$590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$232$91,87420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,395 medical providers in New York.

Other medical in Ithaca

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →